Rheumatology

 

First-Ever Designated Treatment for Lupus Nephritis

September 26, 2020

Today, we talk with Dr. Richard Furie who is chief of rheumatology at Northwell Health in New York. Dr. Furie is the lead investigator of a study on lupus nephritis just published in the New England Journal of Medicine. Dr. Furie and colleagues from the Feinstein Institutes for Medical Research reported that belimumab with standard therapy has been shown to be an effective treatment for lupus nephritis. If the treatment is approved by the U.S. Food and Drug Administration, it would be the first of its kind for this condition. In this presentation, Dr. Furie tell us more.

Post Fracture Oversight Persists in Osteoporosis

September 25, 2020

In a review recently published in Current Osteoporosis Reports, Sarah French, M.D., a rheumatologist with the University of California at San Francisco, summarizes performance quality measures for osteoporosis using Centers for Medicare and Medicaid measures for pay-for-performance programs. In this interview, Dr. French shares with us her findings.

Only 12% of PsA Patients Say Disease Is Under Control

September 25, 2020

The use of biologics, JAK inhibitors and small molecule medications has become increasingly common for patients with psoriatic arthritis. Findings from the recent Psoriatic Arthritis In America 2020 survey by Health Union shows that of 1,120 patients surveyed, most patients (61 percent) are satisfied with the care they receive from their doctors, but they still struggle with flares and only 12 percent are satisfied with their care plan. In this interview, Brian Green, vice president of community development at Health Union, reviews the results of their latest survey.

Type I Interferon Inhibitor May Benefit Lupus

September 24, 2020

Type I Interferon Inhibition Could Benefit Systemic Lupus Erythematosus

Giant Cell Arteritis Diagnosis and Treatment May Undergo Changes

September 24, 2020

The approval of tocilizumab for giant cell arteritis as a glucocorticoid-sparing treatment is the most significant development in the management of this condition over the past four years, a review of the literature suggests.

Reassessing CVD Risk in Rheumatic Disease

September 23, 2020

Some drugs used to treat lupus and other connective tissue diseases have been shown to increase cardiovascular risks. Even so, those drugs remain effective in addressing disease symptoms, and a leading rheumatology researcher has suggested that concerns may not be fully warranted.

The Future of Psoriatic Arthritis Treatment

September 23, 2020

New algorithms and more combination therapeutics are part of the future of psoriatic arthritis care. That’s according to Arthur Kavanaugh, M.D., a rheumatologist with UC San Diego Health who recently presented at the Congress of Clinical Rheumatology East annual meeting held this month.​

Study Highlights Racial Disparities in Knee OA Treatment

September 22, 2020

Black patients with knee osteoarthritis have worse outcomes than their white counterparts, shows a new study.

Diagnostic Options for Cognitive Dysfunction in Lupus

September 22, 2020

Cognitive impairment can be an ongoing issue for patients with rheumatic disease, such as lupus. A proper diagnosis includes a battery of tests, says Noa Shwartz, M.D., a physician-researcher with Albert Einstein College of Medicine in New York.

Polypharmacy Gains Favor in Lupus Nephritis

September 21, 2020

Simultaneous use of more than one drug is gaining traction as a treatment strategy for severe lupus symptoms, particularly in people with chronic kidney disease.